179 related articles for article (PubMed ID: 34271884)
21. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Hauer B; Haas W; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch O; Schönfeld N; Schaberg T
Pneumologie; 2024 Jan; 78(1):35-46. PubMed ID: 37931778
[TBL] [Abstract][Full Text] [Related]
22. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
[TBL] [Abstract][Full Text] [Related]
23. A systematic efficacy analysis of tuberculosis treatment with BPaL-containing regimens using a multiscale modeling approach.
Budak M; Via LE; Weiner DM; Barry CE; Nanda P; Michael G; Mdluli K; Kirschner D
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):673-685. PubMed ID: 38404200
[TBL] [Abstract][Full Text] [Related]
24. Drug resistant TB - latest developments in epidemiology, diagnostics and management.
Tiberi S; Utjesanovic N; Galvin J; Centis R; D'Ambrosio L; van den Boom M; Zumla A; Migliori GB
Int J Infect Dis; 2022 Nov; 124 Suppl 1():S20-S25. PubMed ID: 35342000
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
Solans BP; Imperial MZ; Olugbosi M; Savic RM
Clin Infect Dis; 2023 Jun; 76(11):1903-1910. PubMed ID: 36804834
[TBL] [Abstract][Full Text] [Related]
26. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
27. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
28. Dynamic
Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
[TBL] [Abstract][Full Text] [Related]
29. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
[TBL] [Abstract][Full Text] [Related]
30. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
[TBL] [Abstract][Full Text] [Related]
32. Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Stancil SL; Mirzayev F; Abdel-Rahman SM
Drug Des Devel Ther; 2021; 15():2815-2830. PubMed ID: 34234413
[TBL] [Abstract][Full Text] [Related]
33. Pretomanid: First Approval.
Keam SJ
Drugs; 2019 Nov; 79(16):1797-1803. PubMed ID: 31583606
[TBL] [Abstract][Full Text] [Related]
34. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Riccardi N; Alagna R; Saderi L; Ferrarese M; Castellotti P; Mazzola E; De Lorenzo S; Viggiani P; Udwadia Z; Besozzi G; Cirillo D; Sotgiu G; Codecasa L;
BMC Infect Dis; 2019 Jun; 19(1):564. PubMed ID: 31253115
[TBL] [Abstract][Full Text] [Related]
35. Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
Deb U; Biswas S
Indian J Tuberc; 2021 Apr; 68(2):287-291. PubMed ID: 33845969
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
37. Novel six-month all oral treatment of pre-extensively drug-resistant tuberculosis in Canada: New treatment options present new implementation challenges.
Connors W; Nishi C; Sekirov I; Cook V; Johnston J
Can Commun Dis Rep; 2023 Jan; 49(1):15-20. PubMed ID: 38550769
[TBL] [Abstract][Full Text] [Related]
38. "My Favourite Day Is Sunday": Community Perceptions of (Drug-Resistant) Tuberculosis and Ambulatory Tuberculosis Care in Kara Suu District, Osh Province, Kyrgyzstan.
Burtscher D; Van den Bergh R; Toktosunov U; Angmo N; Samieva N; Rocillo Arechaga EP
PLoS One; 2016; 11(3):e0152283. PubMed ID: 27019454
[TBL] [Abstract][Full Text] [Related]
39. Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Vanino E; Granozzi B; Akkerman OW; Munoz-Torrico M; Palmieri F; Seaworth B; Tiberi S; Tadolini M
Int J Infect Dis; 2023 May; 130 Suppl 1():S12-S15. PubMed ID: 36918080
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
